Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease

Li,Jiling; Feng,Zhengping; Li,Qifu; He,Yan; Zhao,Changhong; He,Jun

doi:10.3892/etm.2014.1688

Insulin glargine effectively achieves glycemic control and improves insulin resistance in patients with early type 2 diabetes that exhibit a high risk for cardiovascular disease

Authors:
- Jiling Li
- Zhengping Feng
- Qifu Li
- Yan He
- Changhong Zhao
- Jun He
View Affiliations

Affiliations: Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: April 24, 2014 https://doi.org/10.3892/etm.2014.1688
Pages: 147-152

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the clinical efficacy and safety of administering insulin glargine to early type 2 diabetes (T2D) mellitus patients with a high risk for cardiovascular disease were assessed. A total of 42 early T2D patients at a high risk for cardiovascular disease were randomly divided into an insulin‑glargine group and a standard‑care group. The patients in the insulin‑glargine group received oral antidiabetic agents plus glargine once a day via a subcutaneous injection. The patients in the standard-care group were administered oral antidiabetic agents according to the diabetic treatment guidelines. The median follow‑up period was 6.4 years. Comparisons were made between the two groups with regard to levels of plasma glucose, glycosylated hemoglobin (HbA1c) and plasma lipids, the homeostasis model assessment‑insulin secretion index (HOMA‑β) and HOMA‑insulin resistance index (HOMA‑IR), as well as the incidence of hypoglycemia, adverse cardiovascular events and body mass index (BMI). The fasting plasma glucose level in the insulin‑glargine group was significantly lower than that observed in the standard‑care group. However, the levels of 2‑h postprandial glucose, HbA1c and plasma lipids, as well as the BMI, were similar when comparing the two groups. Although the level of the HOMA‑β did not differ between the two groups, the level of HOMA‑IR in the insulin‑glargine group was significantly lower than that observed in the standard‑care group. During the follow‑up period, the incidence of hypoglycemia in the insulin‑glargine group was significantly higher when compared with the standard‑care group, however, no significant difference in the incidence of adverse cardiovascular events was observed. Therefore, the results of the present study indicated that insulin glargine may effectively achieve glycemic control and improve insulin resistance without increasing the risk for cardiovascular events in early T2D patients that were considered to be at a high risk for cardiovascular disease.

View Figures

View References

1	Yang W, Lu J, Weng J, et al; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 362:1090–1101. 2010. View Article : Google Scholar : PubMed/NCBI
2	Brunner EJ, Shipley MJ, Witte DR, Fuller JH and Marmot MG: Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care. 29:26–31. 2006.PubMed/NCBI
3	Hu FB, Stampfer MJ, Solomon CG, et al: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 161:1717–1723. 2001.PubMed/NCBI
4	Weng J, Li Y, Xu W, et al: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 371:1753–1760. 2008. View Article : Google Scholar : PubMed/NCBI
5	LeRoith D, Fonseca V and Vinik A: Metabolic memory in diabetes - focus on insulin. Diabetes Metab Res Rev. 21:85–90. 2005. View Article : Google Scholar
6	Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32:193–203. 2009. View Article : Google Scholar
7	Hu Y, Li L, Xu Y, et al: Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and beta-cell function in subjects with long-term remission. Diabetes Care. 34:1848–1853. 2011. View Article : Google Scholar : PubMed/NCBI
8	Lawes CM, Parag V, Bennett DA, et al; Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care. 27:2836–2842. 2004. View Article : Google Scholar : PubMed/NCBI
9	Gerstein HC and Rosenstock J: Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation? Endocrinol Metab Clin North Am. 34:137–154. 2005. View Article : Google Scholar : PubMed/NCBI
10	Younis N, Soran H and Bowen-Jones D: Insulin glargine: a new basal insulin analogue. QJM. 95:757–761. 2002. View Article : Google Scholar : PubMed/NCBI
11	Wang F, Carabino JM and Vergara CM: Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 25:1539–1577. 2003. View Article : Google Scholar : PubMed/NCBI
12	Fonseca V, Gill J, Zhou R and Leahy J: An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab. 13:814–822. 2011. View Article : Google Scholar : PubMed/NCBI
13	Suzuki D, Toyoda M, Kondo M, et al: Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Tokai J Exp Clin Med. 37:35–40. 2012.PubMed/NCBI
14	Pistrosch F, Köhler C, Schaper F, Landgraf W, Forst T and Hanefeld M: Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol. 50:587–595. 2013. View Article : Google Scholar : PubMed/NCBI
15	Xie Y, Mo C, Jin P, et al: The influence of short-term intensive insulin therapy on β-cell function in newly diagnosed type 2 diabetes. Chin J Diabetes. 16:225–227. 2008.
16	Zeng L, Lu H, Deng H, Mu P, Li X and Wang M: Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. Diabetes Technol Ther. 14:35–42. 2012.
17	Toyoda M, Kimura M, Yamamoto N, Miyauchi M, Umezono T and Suzuki D: Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis. J Nephrol. 25:989–995. 2012. View Article : Google Scholar : PubMed/NCBI
18	Delgado E; LAUREL Spain study investigators. Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain. Int J Clin Pract. 66:281–288. 2012. View Article : Google Scholar : PubMed/NCBI
19	Holman RR, Paul SK, Bethel MA, Matthews DR and Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 359:1577–1589. 2008.PubMed/NCBI
20	Zoungas S, Patel A, Chalmers J, et al; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 363:1410–1418. 2010. View Article : Google Scholar : PubMed/NCBI
21	Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 358:2545–2559. 2008. View Article : Google Scholar : PubMed/NCBI
22	Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 358:2560–2572. 2008. View Article : Google Scholar : PubMed/NCBI
23	Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 360:129–139. 2009. View Article : Google Scholar : PubMed/NCBI